Ana de Barros, PhD,  managing science editor—

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will fund a new program to investigate the pathogenesis of Parkinson’s disease called “PATH to PD.” The two-year program includes three research teams that will collaborate to investigate risks associated with genetics, environment and aging, while working with a…

The Michael J. Fox Foundation (MJFF) announced a new $7 million funding program to support Parkinson’s disease research and accelerate development of new therapeutic targets and biomarkers. Through the program, researchers can request project funding in four major research areas. The organization is now accepting pre-proposals through May 2018,…

More than 300 Parkinson’s disease experts and advocates from across the United States will discuss critical needs in research and public policy at a Parkinson’s Policy Forum in Washington, March 19-21. The Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) are sponsoring the initiative. Its goal is…

Neurocrine Biosciences will ask the U.S. Food and Drug Administration in early 2019 to begin the  regulatory review process that could lead to the approval of its Parkinson’s therapy Ongentys (opicapone). It confirmed the timetable after meeting with FDA officials on its plan to file a New Drug Application for Ongentys,…

Parkinson Voice Project, a nonprofit focused on speech therapy, is accepting applications for its National Grant Program that aims to assist nonprofit Parkinson’s groups and patient clinics in bringing its speech therapy approach to patients in their communities. The program will award a total $650,000 in grants to speech therapy clinics…

Stephen Bittel, founder and chairman of Terranova, has donated $450,000 to the Miami-based Parkinson’s Foundation to fund the expansion of its Centers of Excellence network. Bittel also pledged to use his personal and professional networks to raise an additional $1 million for ongoing fellowship grants to encourage young scientists,…

Researchers at Cedars-Sinai found existing evidence does not support claims that wearable biosensors are improving outcomes for patients with various ills — from obesity to hypertension to lung or heart diseases — although hints of these devices’ potential were seen in some studies in Parkinson’s patients. A lack of long-term and…

The winners of a crowd-sourced research challenge designed to improve the ability of remote sensors to monitor Parkinson’s disease (PD) used a mix of signal processing and deep neural networks to better predict disease and disease severity. Sage Bionetworks, in collaboration with the…

The Parkinson’s Foundation has enrolled the 10,000th patient in the largest clinical trial of the disease yet to be conducted. Among the critical discoveries so far, the research has shown that regular visits to neurologists, more exercise, and more attention to mental health could help improve patients’ wellbeing. The…

Adamas Pharmaceuticals is making a concerted effort to spread the word on its flagship treatment for the involuntary muscle movements that are a hallmark of Parkinson’s disease. The U.S. Food and Drug Administration approved Gocovri (amantadine) in August 17. Adamas began making the extended release capsules available in the United States in…